← Zhejiang Huahai Pharmaceutical overview

Zhejiang Huahai Pharmaceutical vs China Resources Double-Crane Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Zhejiang Huahai Pharmaceutical Co Ltd (600521.CG)

Q3 2026
▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

  • Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.

    This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.

  • Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.

    A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.

  • Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.

    Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.

  • US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.

    These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

August 2026
▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

  • Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.

    This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.

  • Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.

    A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.

  • Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.

    Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.

  • US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.

    These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

Latest
▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

  • Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.

    This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.

  • Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.

    A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.

  • Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.

    Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.

  • US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.

    These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

China Resources Double-Crane Pharmaceutical Co Ltd (600062.CG)

Q3 2026
▲3▼1

Double-Crane bets on Lier Chemical while earnings slip and drug pipeline grows

  • 5.66 billion yuan Lier Chemical acquisition Double-Crane won the bid to buy 23.5% of Lier Chemical for 5.656 billion yuan cash, becoming its controlling shareholder. This expands into pesticides and synthetic biology, a long-term growth bet, though it uses a lot of cash and is a major restructuring.

    This is the biggest new event of the period and the main force behind the stock's story.

  • Interim profit and revenue fall First-half 2026 net profit was 946 million yuan, down 3.43%, and revenue fell 3.44% to 5.615 billion yuan. This shows the core business is under pressure, a real counterweight to the acquisition and pipeline news.

    It is the key financial result of the period and the main negative force on the stock.

  • New drug approvals and trial progress The company completed a Phase III trial for pregabalin extended-release tablets and received approvals for acetazolamide capsules, sodium lactate Ringer's irrigation solution, lomustine capsules, and ezetimibe/atorvastatin tablets. These add future revenue sources.

    A steady stream of pipeline wins supports long-term growth even as current earnings dip.

  • Dividend and procurement selection Double-Crane paid a cash dividend of 3.79 yuan per 10 shares and had products proposed for selection in the 12th national centralized drug procurement. Both are shareholder-friendly and support sales volume, though price cuts from procurement can pressure margins.

    These are new capital-return and demand-side events that affect investor income and product demand.

August 2026
▲3▼1

Double-Crane bets on Lier Chemical while earnings slip and drug pipeline grows

  • 5.66 billion yuan Lier Chemical acquisition Double-Crane won the bid to buy 23.5% of Lier Chemical for 5.656 billion yuan cash, becoming its controlling shareholder. This expands into pesticides and synthetic biology, a long-term growth bet, though it uses a lot of cash and is a major restructuring.

    This is the biggest new event of the period and the main force behind the stock's story.

  • Interim profit and revenue fall First-half 2026 net profit was 946 million yuan, down 3.43%, and revenue fell 3.44% to 5.615 billion yuan. This shows the core business is under pressure, a real counterweight to the acquisition and pipeline news.

    It is the key financial result of the period and the main negative force on the stock.

  • New drug approvals and trial progress The company completed a Phase III trial for pregabalin extended-release tablets and received approvals for acetazolamide capsules, sodium lactate Ringer's irrigation solution, lomustine capsules, and ezetimibe/atorvastatin tablets. These add future revenue sources.

    A steady stream of pipeline wins supports long-term growth even as current earnings dip.

  • Dividend and procurement selection Double-Crane paid a cash dividend of 3.79 yuan per 10 shares and had products proposed for selection in the 12th national centralized drug procurement. Both are shareholder-friendly and support sales volume, though price cuts from procurement can pressure margins.

    These are new capital-return and demand-side events that affect investor income and product demand.

Latest
▲3▼1

Double-Crane bets on Lier Chemical while earnings slip and drug pipeline grows

  • 5.66 billion yuan Lier Chemical acquisition Double-Crane won the bid to buy 23.5% of Lier Chemical for 5.656 billion yuan cash, becoming its controlling shareholder. This expands into pesticides and synthetic biology, a long-term growth bet, though it uses a lot of cash and is a major restructuring.

    This is the biggest new event of the period and the main force behind the stock's story.

  • Interim profit and revenue fall First-half 2026 net profit was 946 million yuan, down 3.43%, and revenue fell 3.44% to 5.615 billion yuan. This shows the core business is under pressure, a real counterweight to the acquisition and pipeline news.

    It is the key financial result of the period and the main negative force on the stock.

  • New drug approvals and trial progress The company completed a Phase III trial for pregabalin extended-release tablets and received approvals for acetazolamide capsules, sodium lactate Ringer's irrigation solution, lomustine capsules, and ezetimibe/atorvastatin tablets. These add future revenue sources.

    A steady stream of pipeline wins supports long-term growth even as current earnings dip.

  • Dividend and procurement selection Double-Crane paid a cash dividend of 3.79 yuan per 10 shares and had products proposed for selection in the 12th national centralized drug procurement. Both are shareholder-friendly and support sales volume, though price cuts from procurement can pressure margins.

    These are new capital-return and demand-side events that affect investor income and product demand.